Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2011 1
2016 1
2017 3
2018 7
2019 2
2020 2
2021 1
2022 10
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.
Cooke GS, Flower B, Cunningham E, Marshall AD, Lazarus JV, Palayew A, Jia J, Aggarwal R, Al-Mahtab M, Tanaka Y, Jeong SH, Poovorawan K, Waked I, Hiebert L, Khue PM, Grebely J, Alcantara-Payawal D, Sanchez-Avila JF, Mbendi C, Muljono DH, Lesi O, Desalegn H, Hamid S, de Araujo A, Cheinquer H, Onyekwere CA, Malyuta R, Ivanchuk I, Thomas DL, Pimenov N, Chulanov V, Dirac MA, Han H, Ward JW. Cooke GS, et al. Among authors: marshall ad. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):346-365. doi: 10.1016/S2468-1253(23)00321-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367629 Review.
Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs.
Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, Falade-Nwulia O, Cepeda JA, Cunningham EB, Hajarizadeh B, Lafferty L, Lazarus JV, Bonn M, Marshall AD, Treloar C. Grebely J, et al. Among authors: marshall ad. Int J Drug Policy. 2021 Oct;96:103469. doi: 10.1016/j.drugpo.2021.103469. Epub 2021 Oct 2. Int J Drug Policy. 2021. PMID: 34610884 No abstract available.
A gender lens is needed in hepatitis C elimination research.
Larney S, Madden A, Marshall AD, Martin NK, Treloar C. Larney S, et al. Among authors: marshall ad. Int J Drug Policy. 2022 May;103:103654. doi: 10.1016/j.drugpo.2022.103654. Epub 2022 Mar 17. Int J Drug Policy. 2022. PMID: 35306279
Perspectives and sentiments on contingency management from people who use methamphetamine.
Clay S, Wilkinson Z, Ginley M, Arunogiri S, Christmass M, Membrey D, MacCartney P, Sutherland R, Colledge-Frisby S, Marshall AD, Nagle J, Degenhardt L, Farrell M, McKetin R. Clay S, et al. Among authors: marshall ad. Drug Alcohol Rev. 2023 Sep;42(6):1427-1437. doi: 10.1111/dar.13691. Epub 2023 May 29. Drug Alcohol Rev. 2023. PMID: 37248676
43 results